GlaxoSmithKline plc (NYSE:GSK) has been given a consensus recommendation of “Hold” by the twenty-one research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $43.00.
A number of equities analysts have recently commented on GSK shares. Zacks Investment Research raised shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Morgan Stanley started coverage on shares of in a research report on Monday, June 17th. They set an “equal weight” rating and a GBX 215 ($2.81) target price on the stock.
NYSE GSK traded down $0.51 during trading on Tuesday, hitting $40.42. The stock had a trading volume of 4,313,971 shares, compared to its average volume of 2,128,528. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. The stock has a market cap of $100.27 billion, a PE ratio of 12.79, a price-to-earnings-growth ratio of 2.10 and a beta of 0.74. GlaxoSmithKline has a one year low of $36.41 and a one year high of $42.32. The firm’s 50 day moving average price is $40.07.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.13. The business had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 157.04%. On average, sell-side analysts expect that GlaxoSmithKline will post 2.91 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Stockholders of record on Friday, May 17th were given a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.90%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 58.86%.
In related news, Director Plc Glaxosmithkline bought 385,714 shares of GlaxoSmithKline stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $14.00 per share, with a total value of $5,399,996.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have bought 1,044,047 shares of company stock worth $16,249,991. Corporate insiders own 10.00% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Nachman Norwood & Parrott Inc purchased a new position in GlaxoSmithKline during the first quarter valued at approximately $201,000. Sphera Funds Management LTD. increased its holdings in GlaxoSmithKline by 38.7% during the first quarter. Sphera Funds Management LTD. now owns 430,000 shares of the pharmaceutical company’s stock valued at $17,970,000 after buying an additional 120,000 shares during the period. Wrapmanager Inc. increased its holdings in GlaxoSmithKline by 13.7% during the first quarter. Wrapmanager Inc. now owns 36,845 shares of the pharmaceutical company’s stock valued at $1,540,000 after buying an additional 4,434 shares during the period. PagnatoKarp Partners LLC increased its holdings in GlaxoSmithKline by 5.9% during the first quarter. PagnatoKarp Partners LLC now owns 7,384 shares of the pharmaceutical company’s stock valued at $313,000 after buying an additional 411 shares during the period. Finally, Pathlight Investors LLC purchased a new position in GlaxoSmithKline during the fourth quarter valued at approximately $675,000. 11.26% of the stock is currently owned by institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What is a capital gain?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.